Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis

It has been more than a year since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged. Many studies have provided insights into the various aspects of the immune response in coronavirus disease 2019 (COVID-19). Especially for antibody treatment and vaccine development, humora...

Full description

Saved in:
Bibliographic Details
Published inMolecules and cells Vol. 44; no. 6; pp. 392 - 400
Main Authors Lee, Eunjin, Oh, Ji Eun
Format Journal Article
LanguageEnglish
Published United States Korean Society for Molecular and Cellular Biology 01.06.2021
한국분자세포생물학회
Subjects
Online AccessGet full text
ISSN1016-8478
0219-1032
DOI10.14348/molcells.2021.0075

Cover

More Information
Summary:It has been more than a year since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged. Many studies have provided insights into the various aspects of the immune response in coronavirus disease 2019 (COVID-19). Especially for antibody treatment and vaccine development, humoral immunity to SARS-CoV-2 has been studied extensively, though there is still much that is unknown and controversial. Here, we introduce key discoveries on the humoral immune responses in COVID-19, including the immune dynamics of antibody responses and correlations with disease severity, neutralizing antibodies and their cross-reactivity, how long the antibody and memory B-cell responses last, aberrant autoreactive antibodies generated in COVID-19 patients, and the efficacy of currently available therapeutic antibodies and vaccines against circulating SARS-CoV-2 variants, and highlight gaps in the current knowledge.
ISSN:1016-8478
0219-1032
DOI:10.14348/molcells.2021.0075